VBI acquires Epixis
The acquisition allows VBI to develop its own VLP-based vaccines by leveraging its suite of thermostable vaccine formulation technologies. The terms of the deal were not disclosed. VBI
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.